Zovighian Bernard J's Form 4 filing
Edwards Lifesciences CorpEW · filed May 12, 2026
- Accession no.
- 0001225208-26-005172
- Filed
- May 12, 2026
- Trade date
- May 11-12, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.83M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zovighian Bernard JCIK 0001665141 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common Stock | MOption exerciseAcquired | +47,207 | $0.00F1 | $0 | 157,491.65 | Direct | |
| May 11, 2026 | Common Stock | FTax withholdingDisposed | −26,198 | $79.96 | −$2,094,792.08 | 125,804.65 | Direct | |
| May 12, 2026 | Common Stock | GGiftDisposed | −26,640 | $0.00 | $0 | 99,164.65 | Direct | |
| May 12, 2026 | Common Stock | GGiftAcquired | +26,640 | $0.00 | $0 | 48,390.55 | Indirect | |
| May 12, 2026 | Common Stock | SSaleDisposed | −845 | $78.40F3 | −$66,248 | 47,545.55 | Indirect | |
| May 12, 2026 | Common Stock | SSaleDisposed | −35,506 | $77.92F4 | −$2,766,627.52 | 12,039.55 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common Stock | MOption exerciseDisposed | −47,207 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.